Clinical Trial

Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma.

Study acronym: FIBIOME
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The underlying hypothesis of the study is that melanoma patients treated with immunotherapy, whether in an adjuvant or curative setting, who consume more fiber would respond better to immunotherapy: either no recurrence in the case of adjuvant treatments, or no progression (disease stability, partial or complete response) in the case of curative treatments. The primary objective is to evaluate the association between total dietary fiber intake quantified using the FiberTAG questionnaire and response to immunotherapy treatment in patients treated for melanoma in a curative or adjuvant setting
Trial Details
NCT Number NCT07437300
Lead Sponsor University Hospital, Grenoble
Conditions Melanoma
Enrollment 60 participants
Start Date 2026-02-25
Primary Completion 2026-05-15 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-27